Core Insights - Elanco Animal Health Incorporated is a significant player in the animal health industry, focusing on enhancing animal care through various products and services [1] - The company is led by CEO Jeff Simmons, who emphasizes growth and maintaining a strong market position amidst competition [1] Financial Performance - Stifel Nicolaus has set a price target of $27 for Elanco, indicating a potential increase of approximately 23.26% from its current price of $21.91 [2][6] - The stock is currently trading at $21.94, reflecting a slight decrease of 2.49% with a change of $0.56 [2] - Elanco's stock has shown volatility, with a daily trading range from $21.38 to $22.98, and over the past year, it reached a high of $22.96 and a low of $8.02 [4] Market Position and Consumer Behavior - CEO Jeff Simmons highlighted that consumer willingness to spend on animal care remains strong even during challenging economic times, indicating stable demand for Elanco's products [3][6] - The company is focusing on resource allocation to sustain its market position and adapt to consumer trends [3] Market Capitalization and Trading Activity - Elanco maintains a market capitalization of approximately $10.9 billion, reflecting its substantial presence in the animal health industry [4][6] - The trading volume for ELAN is 9,189,975 shares, indicating active investor interest in the company's stock [5]

So joining me now in a first on CNBC interview is Ela Co. Animal Health CEO Jeff Simmons. Jeff, we've spoken numerous times before.At this point, you know, I have multiple dogs in my household. Like many millions of Americans, we care about their health. What's been driving Ela Co's results, specifically when it comes to the pets versus the farm side of things.>> Yeah, Dom, thanks for the time. Yeah, we delivered a great quarter. 9% organic constant currency growth.That really marks uh nine consecutive quar ...

So joining me now in a first on CNBC interview is Ela Co. Animal Health CEO Jeff Simmons. Jeff, we've spoken numerous times before.At this point, you know, I have multiple dogs in my household. Like many millions of Americans, we care about their health. What's been driving Ela Co's results, specifically when it comes to the pets versus the farm side of things.>> Yeah, Dom, thanks for the time. Yeah, we delivered a great quarter. 9% organic constant currency growth.That really marks uh nine consecutive quar ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) INDIANA 82-54 ...

Elanco Animal Health (NYSE:ELAN) Q3 2025 Earnings Call November 05, 2025 08:00 AM ET Company ParticipantsJeff Simmons - President and CEOBob VanHimbergen - CFOTiffany Kanaga - VP of Investor RelationsJon Block - Managing DirectorDaniel Clark - VP of Equity ResearchUmer Raffat - Senior Managing DirectorConference Call ParticipantsLinda Bolduc - AnalystNone - AnalystMichael Ryskin - Managing Director and Senior Equity Research AnalystAndrea Alfonso - Equity AnalystBrandon Vazquez - Research AnalystNavann Ty - ...

Elanco Animal Health (NYSE:ELAN) Q3 2025 Earnings Call November 05, 2025 08:00 AM ET Company ParticipantsJeff Simmons - President and CEOBob VanHimbergen - CFOTiffany Kanaga - VP of Investor RelationsJon Block - Managing DirectorDaniel Clark - VP of Equity ResearchUmer Raffat - Senior Managing DirectorConference Call ParticipantsLinda Bolduc - AnalystNone - AnalystMichael Ryskin - Managing Director and Senior Equity Research AnalystAndrea Alfonso - Equity AnalystBrandon Vazquez - Research AnalystNavann Ty - ...

Financial Data and Key Metrics Changes - Elanco reported revenue of $1.137 billion for Q3 2025, representing a 10% increase on a reported basis and 9% organic constant currency growth, primarily driven by volume increases [20][21] - Adjusted EBITDA was $198 million, an increase of $35 million year-over-year, while adjusted EPS rose to $0.19, up $0.06 from the previous year [22] - The net leverage ratio improved to 3.7 times, better than expectations, with a goal to end the year between 3.7-3.8 times [5][22] Business Line Data and Key Metrics Changes - U.S. Pet Health revenue grew by 9%, driven by key products like Credelio Quattro and Zenrelia, while international pet health saw an 8% increase [20][21] - U.S. Farm Animal business achieved a remarkable 20% growth, supported by strong performance in cattle and poultry vaccines [20][21] - International Farm Animal revenue increased by 5%, with growth attributed to poultry and ruminants [7][20] Market Data and Key Metrics Changes - The overall pet health market in the U.S. is experiencing strong growth, with the broad spectrum endecto market reaching $1.4 billion and growing at nearly 40% [9][34] - The global dermatology market is also expanding, with Zenrelia capturing approximately 5% market share in countries where it has launched [12][14] - The farm animal sector is benefiting from a historically small U.S. cattle herd, driving demand for products like Experior, which grew 70% in Q3 [15][51] Company Strategy and Development Direction - Elanco is focused on innovation, portfolio management, and productivity, with a strong emphasis on cash generation and operational execution [4][19] - The company is raising its full-year expectations for innovation revenue to $840 million-$880 million, reflecting broad-based momentum across its product portfolio [4][6] - The strategy includes geographic expansion and leveraging differentiated products to capture market share in both pet and farm animal segments [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges, including tariff impacts, while maintaining strong growth momentum [5][25] - The outlook for 2026 includes expectations for continued revenue growth driven by innovation and a stabilizing base business, despite competitive pressures [27][28] - Management highlighted the importance of maintaining a balanced approach to guidance, considering both competitive dynamics and macroeconomic factors [41][42] Other Important Information - The company successfully refinanced its $2.1 billion term loan B facility, extending maturities and reducing the cost of debt [5][23] - Elanco's innovation pipeline is robust, with several products expected to launch in 2026, including IL31, which is currently under USDA review [17][19] - The company is committed to enhancing productivity through initiatives like Elanco Ascend, aimed at driving efficiencies across the organization [19][49] Q&A Session Summary Question: Clarification on Credelio Quattro's sales - Management clarified that Credelio Quattro reached $100 million in net sales since its launch, not just in Q3, and expressed optimism about its potential peak sales [31][34] Question: Insights on Zenrelia's label update and market share - Management discussed the positive momentum for Zenrelia, highlighting its growing market share and the recent removal of vaccine-induced disease language from its label [35][36] Question: 2025 EBITDA guidance and OpEx investments - Management confirmed the increase in EBITDA guidance and discussed the ongoing investments in operational expenses to support product launches and growth [38][39] Question: Competitive landscape and market dynamics - Management acknowledged the competitive pressures in the derm and parasiticides markets but emphasized that their differentiated portfolio has allowed them to maintain market share [53]

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +46.15%. A quarter ago, it was expected that this company would post earnings of $0.2 per share when it actually produced earnings of $0.26, delivering a surprise of +30%.Over the last four quarte ...

D 2025 Earnings – Third Quarter November 5, 2025 2025 | Q3 Earnings Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and fourth quarter guidance, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance a ...